Astec Lifesciences Q4 FY26: Sales Jump 32.7%, Loss Shrinks 52%, But ₹449 Cr Debt and Negative ROE Keep the Detective Busy
1. At a Glance
Astec Lifesciences has delivered the kind of Q4 FY26 result that looks better only because the previous picture was extremely bruised.
Sales rose to ₹158.62 crore in Q4 FY26 from ₹119.53 crore in Q4 FY25. Net loss reduced to ₹7.75 crore from ₹16.08 crore. Operating profit came back to ₹9.16 crore, compared with ₹5.53 crore last year and ₹3.98 crore in the previous quarter.
So yes, the fire is smaller.
But the building is still smoky.
For FY26, Astec reported sales of ₹448 crore, operating loss of ₹5 crore, net loss of ₹81 crore, and EPS of negative ₹36.32. The company’s ROE stands at negative 25.2%, ROCE at negative 5.45%, and debt is still ₹449 crore.
This is not a clean turnaround story yet. This is a “the patient has opened one eye” story.
The stock trades at ₹726, with a market cap of ₹1,619 crore. Book value is ₹175, meaning the stock trades at roughly 4.13 times book value. For a company with negative earnings, negative ROE, negative ROCE, and high debtor days of 202, that is not cheap in the usual accountant’s dictionary. The market is clearly not valuing current profitability. It is valuing recovery, parentage, CDMO optionality, agrochemical cycle revival, and perhaps a little hope served with Godrej branding.
Astec is part of the Godrej Agrovet ecosystem. Promoter holding is 71.97%, with Godrej Agrovet holding 67.03%. That parent comfort matters because weak operational performance has been visible for multiple years. The March 2026 rating update also points to weak performance over FY24 to 9M FY26, high competition from Chinese players, pressure in key products, and the importance of parent support.
The detective’s first clue: Q4 improved.
The second clue: full-year FY26 is still deeply loss-making.
The third clue: rights issue, management changes, CFO changes, and related party approvals suggest this is not a quiet year. This is a company in repair mode.
Question for readers: is this a turnaround, or simply a cyclical company taking a breather after getting punched by China, inventory, demand slowdown, and debt?
2. Introduction
Astec Lifesciences manufactures agrochemical active ingredients, intermediates, bulk products, and formulations. It sells in India and exports to around 24 countries. It is purely B2B, so there are no fancy consumer brands to show on Instagram. This is chemistry, contracts, plants, clients, and margins.
The company operates in fungicides, insecticides, herbicides, intermediates, triazole fungicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, ketones, ethers, alcohols, and related chemical compounds.
In simpler language: Astec makes the chemical building blocks that help agriculture input companies sell products to farmers and global customers.
Historically, Astec had strong years. FY22 sales were ₹677 crore, operating profit was ₹154 crore, and net profit was ₹90 crore. EPS was ₹40.12.
Then the story cracked.
FY24 sales fell to ₹458 crore and net loss was ₹47 crore. FY25 sales fell further to ₹381 crore and net loss widened to ₹135 crore. FY26 shows some recovery in revenue to ₹448 crore, but the company still posted a net loss of ₹81 crore.
So the direction has improved, but the destination is still far away.
The key question is not whether Q4 FY26 was better. It clearly was.
The real question is whether Astec can convert revenue recovery into durable margins, positive cash flow, lower debt stress, and respectable return ratios.
Because right now, the company is like a chemical reactor that has finally stopped leaking smoke, but the auditor is still standing nearby with a fire extinguisher and a suspicious expression.
3. Business Model – WTF Do They Even Do?
Astec Lifesciences is an agrochemical B2B manufacturer.
It sells technical-grade agrochemical products, intermediates, and contract manufacturing products. Its business has two broad parts:
Segment
What it Means
Enterprise business
Own agrochemical products, mainly technical-grade molecules
Contract manufacturing / CDMO
Manufacturing products or intermediates for global clients
In FY23, the revenue mix was:
Segment
Revenue Share
Enterprise
74%
Contract Manufacturing
26%
Geographically, FY23 revenue was:
Market
Share
Domestic
39%
International
61%
The company operates four manufacturing facilities, including a greenfield herbicide plant commissioned in August 2021. It has also been working towards Zero Liquid Discharge status, which is important because chemical plants without environmental discipline can become financial horror films.
In FY23, the company inaugurated the Adi Godrej Center for Chemical Research and Development at Rabale, Maharashtra. This R&D centre is meant to support synthesis, formulation labs, safety infrastructure, and CDMO expansion.
The strategy sounds logical: reduce dependence on a few generic products, move towards higher-margin CDMO, diversify into herbicides, scale R&D, and expand customers.
But strategy and execution are different animals.
The old promise was diversification and CDMO scale-up. The latest data shows CMO revenue contribution moved sharply to 60% in FY24 and 46% in FY25. That suggests the company did move in the direction it spoke about. But margins and losses show that “walking the talk” did not yet translate into shareholder-friendly economics.
Management moved the chess pieces. The board is still waiting for checkmate.
4. Financials Overview
Quarterly Comparison
Metric
Latest Quarter: Mar 2026
Same Quarter Last Year: Mar 2025
Previous Quarter: Dec 2025
Revenue
₹158.62 cr
₹119.53 cr
₹124.72 cr
EBITDA / Operating Profit
₹9.16 cr
₹5.53 cr
₹3.98 cr
PAT
-₹7.75 cr
-₹16.08 cr
-₹15.69 cr
EPS
-₹3.48
-₹7.18
-₹7.05
Q4 FY26 is clearly better. Revenue grew 32.7% YoY. Loss reduced sharply. Operating profit turned healthier versus both YoY and QoQ.
But the full year still looks weak.
Full-Year Snapshot
Metric
FY24
FY25
FY26
Sales
₹458 cr
₹381 cr
₹448 cr
Operating Profit
-₹6 cr
-₹66 cr
-₹5 cr
Net Profit
-₹47 cr
-₹135 cr
-₹81 cr
EPS
-₹20.95
-₹60.16
-₹36.32
The FY26 improvement is visible. Losses have reduced. Operating loss is almost flat near breakeven.
But “almost breakeven” is not the same as “profitable.”
Astec is still losing money after interest and depreciation. Interest cost in FY26 was ₹35 crore. Depreciation was ₹45 crore. That means even if operating profit stabilises, finance cost and depreciation will keep asking uncomfortable questions.
Did management walk the talk?
Partly.
They spoke about R&D, CDMO expansion, diversification, and better capacity utilisation. CMO contribution improved in recent years, R&D expenditure as a percentage of turnover rose strongly versus older years, and the herbicide plant utilisation reached 100% in FY25 as per the available insight data.
But the financial scorecard says: operational progress has not yet become financial strength.
Question for readers: should investors reward the direction of improvement, or punish the absolute level of losses?
A negative P/E is not useful for fair valuation because the company is loss-making. Applying peer P/E to negative earnings gives no sensible fair value.
Again, this is not analytically useful. EV/EBITDA works when EBITDA is positive. Here, EBITDA is negative for FY26.
So EV/EBITDA method result: Not Meaningful
Method 3: DCF Valuation
DCF needs sustainable free cash flow.
Astec’s recent free cash flow:
Year
Free Cash Flow
FY24
-₹125 cr
FY25
-₹24 cr
FY26
-₹86 cr
Since free cash flow is negative across the last three reported years, a clean DCF cannot be built without making assumptions about future recovery. Under the strict data-only approach, using invented growth rates or terminal values would be financial fiction wearing a spreadsheet tie.
So DCF method result: Not Meaningful from available positive cash flows
Educational Fair Value Range
Based strictly on the three requested valuation methods:
Method
Output
P/E
Not meaningful due to negative EPS
EV/EBITDA
Not meaningful due to negative EBITDA
DCF
Not meaningful due to negative FCF
Therefore, a reliable earnings-backed fair value range cannot be derived from the current reported data.
The only hard anchor visible is book value of ₹175 per share, while the market price is ₹726, or around 4.13 times book value. That does not prove overvaluation by itself, but it does show that the market is paying for recovery expectations, not current earnings.
This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Astec had no shortage of corporate action drama.
The Board approved FY26 audited results, fixed the 32nd AGM for 31 July 2026, and proposed postal ballot approvals for director appointments and material related party transactions during FY27.
There was also a management reshuffle. Nadir Godrej retired, Vishal Sharma became chairperson, Burjis Godrej resigned as Managing Director, and new
